Moreover, a cross-talk between PARP1 and androgen receptor (AR) function has been proposed as the basis of the benefit of the combination of PARPi with AR inhibitors regardless of the HRD status of the tumour [85,86,87]. This evidence concerns the gene PARP1 and neoplasm.